Education
About Us
Working with TipRanks
Follow Us
LAVA Therapeutics (LVTX)
NASDAQ:LVTX
LVTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $3.57
Previous CloseN/A
Volume31.56K
Average Volume (3M)801.15K
Market Cap
$31.04M
Enterprise Value-$28.03M
Total Cash (Recent Filing)-$6.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 14, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding26,305,296
10 Day Avg. Volume47,767
30 Day Avg. Volume801,154
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.34
Enterprise Value/Ebitda1.02
Forecast
1Y Price Target
$1.25Price Target Upside7.76% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
LAVA Therapeutics News
PremiumCompany Announcements
Lava Therapeutics Reports 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported license revenue of $5M and a net loss of $0.14 per share, better than the consensus estimate of revenue of $2.5M and a net loss of 0.30 per share.
PartnershipsA $5MM milestone payment was received from a partnership with JNJ, following the revelation of CD33 as the target for its partnered asset.
Strategic ReviewLava's ongoing strategic review may conclude in a value-accretive outcome for the company.
Bears Say
Clinical DataThe company's sole remaining wholly-owned clinical asset, LAVA-1266, lacks supportive clinical data.
Program RisksThere is a great risk for LAVA-1266 to be de-prioritized to accommodate development of new programs in the event of acquiring new assets or undergoing a reverse merger.
UncertaintiesUncertainties are generated regarding the company’s only clinical asset, LAVA-1266 for hematological malignancies, as it depends on the outcome of the strategic review.
---
Ownership Overview
―
Insiders
2.98% Mutual Funds
23.53% Other Institutional Investors
73.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LVTX FAQ
What was LAVA Therapeutics’s price range in the past 12 months?
LAVA Therapeutics lowest stock price was $0.85 and its highest was $3.57 in the past 12 months.
What is LAVA Therapeutics’s market cap?
LAVA Therapeutics’s market cap is $31.04M.
When is LAVA Therapeutics’s upcoming earnings report date?
LAVA Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 38 days.
How were LAVA Therapeutics’s earnings last quarter?
LAVA Therapeutics released its earnings results on Mar 28, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.295 by $0.155.
Is LAVA Therapeutics overvalued?
According to Wall Street analysts LAVA Therapeutics’s price is currently Undervalued.
Does LAVA Therapeutics pay dividends?
LAVA Therapeutics does not currently pay dividends.
What is LAVA Therapeutics’s EPS estimate?
LAVA Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does LAVA Therapeutics have?
LAVA Therapeutics has 26,305,296 shares outstanding.
What happened to LAVA Therapeutics’s price movement after its last earnings report?
LAVA Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.295. Following the earnings report the stock price went down -0.769%.
Which hedge fund is a major shareholder of LAVA Therapeutics?
Currently, no hedge funds are holding shares in LVTX
---
LAVA Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.25 (7.76% Upside)
$1.25 (7.76% Upside)
Hedge Fund Trend
Decreased
By 87.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.05%
12-Months-Change
Fundamentals
Return on Equity
-63.12%
Trailing 12-Months
Asset Growth
-24.92%
Trailing 12-Months
Company Description
LAVA Therapeutics
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
---
LVTX Stock 12 Month Forecast
Average Price Target
$1.25
▲(7.76% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
Immatics
―
Best Analysts Covering LVTX
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-8.65%
reiterated a buy rating 8 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -8.65% per trade.
---